Defending Public Health: Strategies to safeguard pharmaceutical quality: Raheel Shah, Business Development Director, BDR Pharmaceuticals

This exposé embarks on an illuminative journey, unfurling the crucial stratagems imperative for upholding public health, achieved through the unyielding fortress of pharmaceutical quality safeguards

Amgen olpasiran may fill critical treatment gap in lowering Lp(a): GlobalData

This study showed that patients taking 75mg of Olpasiran previously every 12 weeks presented a 40–50% reduction in LP(a)

Global Digital Health Summit outlines roadmap for making India a global leader in digital health implementation

Sanofi, Meningitis Research Foundation and CoMO launch awareness initiative on meningitis

Meningitis still affects more than 2.5 million people globally each year

USFDA approves BMS’ Reblozyl as first-line treatment of anemia in adults with Myelodysplastic Syndromes

Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia

European Commission approves Keytruda plus Trastuzumab and chemotherapy as first-line treatment for GEJ

KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population

Bayer appoints Dr. Juergen Eckhardt as new Head of Pharmaceuticals Business Development & Licensing/Open Innovation

Juergen Eckhardt joined Bayer in 2016 to help start Leaps by Bayer

Zydus to present on ZYIL1 at the International Congress of Parkinson's Disease and Movement Disorders

In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers

Lynparza plus abi/pred approved in Japan for treatment of prostate cancer

First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent

Glenmark Pharmaceuticals USA reaches antitrust settlement with DOJ

The company has entered into a three-year Deferred Prosecution Agreement